Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

November 2014 - FRMC

11/14/2014
In a new study, researchers investigated the demographic and clinical factors of patients initiating canagliflozin or DPP-4 therapy in a large commercially insured US population.
In a new study, researchers investigated the demographic and clinical factors of patients initiating canagliflozin or DPP-4 therapy in a large commercially insured US population.
In a new study, researchers...
11/14/2014
First Report Managed Care
11/14/2014
Clinical data from the EVIDENCE study found that the cost-effectiveness of subcutaneous interferon (IFN) ß-1a 44 mcg given 3 times weekly was favorable compared with intramuscular IFN ß-1a 30 mcg given once weekly for relapsing forms of...
Clinical data from the EVIDENCE study found that the cost-effectiveness of subcutaneous interferon (IFN) ß-1a 44 mcg given 3 times weekly was favorable compared with intramuscular IFN ß-1a 30 mcg given once weekly for relapsing forms of...
Clinical data from the EVIDENCE...
11/14/2014
First Report Managed Care
11/14/2014
Breakthrough therapy designation was established as part of the FDA Safety and Innovation Act of 2012.
Breakthrough therapy designation was established as part of the FDA Safety and Innovation Act of 2012.
Breakthrough therapy designation...
11/14/2014
First Report Managed Care
11/14/2014
A recent study evaluated formulary cost implications associated with the addition of naltrexone/bupropion for the treatment of obesity in the United States.
A recent study evaluated formulary cost implications associated with the addition of naltrexone/bupropion for the treatment of obesity in the United States.
A recent study evaluated...
11/14/2014
First Report Managed Care
11/14/2014
A pharmacy budget impact model to estimate, from a payer perspective, the impact of the introduction of tbo-filgrastim as an alternative short-acting granulocyte colony-stimulating factor on a pharmacy budget showed a total annual plan cost...
A pharmacy budget impact model to estimate, from a payer perspective, the impact of the introduction of tbo-filgrastim as an alternative short-acting granulocyte colony-stimulating factor on a pharmacy budget showed a total annual plan cost...
A pharmacy budget impact model...
11/14/2014
First Report Managed Care
11/14/2014
As patented products expire, >$13 billion in brand-name specialty medications are expected to face generic competition in the next 5 years, and it is projected that there is a $31.8 billion opportunity in the market for biosimilars through...
As patented products expire, >$13 billion in brand-name specialty medications are expected to face generic competition in the next 5 years, and it is projected that there is a $31.8 billion opportunity in the market for biosimilars through...
As patented products expire,...
11/14/2014
First Report Managed Care
11/14/2014
As with other specialty drugs, the high cost of medications to treat hepatitis C presents payers with the challenge of helping their members get the medications they need, while attempting to maintain healthcare costs.
As with other specialty drugs, the high cost of medications to treat hepatitis C presents payers with the challenge of helping their members get the medications they need, while attempting to maintain healthcare costs.
As with other specialty drugs,...
11/14/2014
First Report Managed Care

News

News
11/14/2014
The economic burden of psoriasis in the United States is significant, as it is estimated to cost $11.25 billion annually in total direct and indirect healthcare costs, according to statistics from the National Psoriasis Foundation.
The economic burden of psoriasis in the United States is significant, as it is estimated to cost $11.25 billion annually in total direct and indirect healthcare costs, according to statistics from the National Psoriasis Foundation.
The economic burden of psoriasis...
11/14/2014
First Report Managed Care

Department

Conference Insider
11/14/2014
Legislation on medication therapy management expansion and Medicare drug price negotiations are being discussed on the federal level, while states are considering legislation in the areas of biosimilars, controlled substances, and benefit...
Legislation on medication therapy management expansion and Medicare drug price negotiations are being discussed on the federal level, while states are considering legislation in the areas of biosimilars, controlled substances, and benefit...
Legislation on medication...
11/14/2014
First Report Managed Care
Conference Insider
11/14/2014
“This is a large paradigm change for clinicians,” said Joseph Saseen, PharmD, professor, vice chair, department of clinical pharmacy, professor, department of family medicine, University of Colorado Skaggs School of Pharmacy and...
“This is a large paradigm change for clinicians,” said Joseph Saseen, PharmD, professor, vice chair, department of clinical pharmacy, professor, department of family medicine, University of Colorado Skaggs School of Pharmacy and...
“This is a large paradigm change...
11/14/2014
First Report Managed Care

Advertisement

Advertisement

Advertisement